Last reviewed · How we verify
acetaminophen IV
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.
Acetaminophen inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever. Used for Acute pain management, Fever reduction.
At a glance
| Generic name | acetaminophen IV |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX) enzymes |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen works primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production. This leads to decreased pain perception and hypothalamic temperature regulation. The intravenous formulation provides rapid systemic delivery for acute pain and fever management in clinical settings.
Approved indications
- Acute pain management
- Fever reduction
Common side effects
- Hepatotoxicity
- Nausea
- Vomiting
- Injection site reactions
Key clinical trials
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- acetaminophen IV CI brief — competitive landscape report
- acetaminophen IV updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI